188 related articles for article (PubMed ID: 36198031)
1. NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.
Llaurado Fernandez M; Hijmans EM; Gennissen AMC; Wong NKY; Li S; Wisman GBA; Hamilton A; Hoenisch J; Dawson A; Lee CH; Bittner M; Kim H; DiMattia GE; Lok CAR; Lieftink C; Beijersbergen RL; de Jong S; Carey MS; Bernards R; Berns K
Mol Cancer Ther; 2022 Dec; 21(12):1862-1874. PubMed ID: 36198031
[TBL] [Abstract][Full Text] [Related]
2. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer.
Mert I; Chhina J; Allo G; Dai J; Seward S; Carey MS; Llaurado M; Giri S; Rattan R; Munkarah AR
Gynecol Oncol; 2017 Aug; 146(2):319-326. PubMed ID: 28545687
[TBL] [Abstract][Full Text] [Related]
4. Advances in precision therapy of low-grade serous ovarian cancer: A review.
Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B
Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365
[TBL] [Abstract][Full Text] [Related]
5. Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.
Grisham RN; Chui MH
Curr Oncol Rep; 2022 Nov; 24(11):1549-1555. PubMed ID: 35962920
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a
Colombo I; Garg S; Danesh A; Bruce J; Shaw P; Tan Q; Quevedo R; Braunstein M; Oza AM; Pugh T; Lheureux S
Cold Spring Harb Mol Case Stud; 2019 Dec; 5(6):. PubMed ID: 31836588
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review.
Lazurko C; Linder R; Pulman K; Lennox G; Feigenberg T; Fazelzad R; May T; Zigras T
Curr Oncol; 2023 Sep; 30(9):8159-8171. PubMed ID: 37754507
[TBL] [Abstract][Full Text] [Related]
8. Low-grade Serous Tumors: Are We Making Progress?
Pauly N; Ehmann S; Ricciardi E; Ataseven B; Bommert M; Heitz F; Prader S; Schneider S; du Bois A; Harter P; Baert T
Curr Oncol Rep; 2020 Jan; 22(1):8. PubMed ID: 31989304
[TBL] [Abstract][Full Text] [Related]
9. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
Hollis RL; Elliott R; Dawson JC; Ilenkovan N; Matthews RM; Stillie LJ; Oswald AJ; Kim H; Llaurado Fernandez M; Churchman M; Porter JM; Roxburgh P; Unciti-Broceta A; Gershenson DM; Herrington CS; Carey MS; Carragher NO; Gourley C
Gynecol Oncol; 2024 Apr; 186():42-52. PubMed ID: 38582027
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer.
Kurimchak AM; Shelton C; Herrera-Montávez C; Duncan KE; Chernoff J; Duncan JS
Mol Cancer Res; 2019 Aug; 17(8):1721-1734. PubMed ID: 31043489
[TBL] [Abstract][Full Text] [Related]
11. Targeting RAS-ERK pathway alterations with MEK inhibitors to improve chemosensitivity in high grade serous ovarian cancers.
Nguyen NT; Raetz A; Montoya D; Schilling V; Tong C; Brooks RA; Leiserowitz G; Chien J
Gynecol Oncol; 2023 Nov; 178():69-79. PubMed ID: 37806229
[TBL] [Abstract][Full Text] [Related]
12. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
13. Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.
Sulahian R; Kwon JJ; Walsh KH; Pailler E; Bosse TL; Thaker M; Almanza D; Dempster JM; Pan J; Piccioni F; Dumont N; Gonzalez A; Rennhack J; Nabet B; Bachman JA; Goodale A; Lee Y; Bagul M; Liao R; Navarro A; Yuan TL; Ng RWS; Raghavan S; Gray NS; Tsherniak A; Vazquez F; Root DE; Firestone AJ; Settleman J; Hahn WC; Aguirre AJ
Cell Rep; 2019 Oct; 29(1):118-134.e8. PubMed ID: 31577942
[TBL] [Abstract][Full Text] [Related]
14. The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
Hendrikse CSE; Theelen PMM; van der Ploeg P; Westgeest HM; Boere IA; Thijs AMJ; Ottevanger PB; van de Stolpe A; Lambrechts S; Bekkers RLM; Piek JMJ
Gynecol Oncol; 2023 Apr; 171():83-94. PubMed ID: 36841040
[TBL] [Abstract][Full Text] [Related]
15. Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target.
Fernandez ML; Dawson A; Hoenisch J; Kim H; Bamford S; Salamanca C; DiMattia G; Shepherd T; Cremona M; Hennessy B; Anderson S; Volik S; Collins CC; Huntsman DG; Carey MS
Cancer Cell Int; 2019; 19():10. PubMed ID: 30636931
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma.
De Thaye E; Van de Vijver K; Van der Meulen J; Taminau J; Wagemans G; Denys H; Van Dorpe J; Berx G; Ceelen W; Van Bocxlaer J; De Wever O
Sci Rep; 2020 Apr; 10(1):6688. PubMed ID: 32317693
[TBL] [Abstract][Full Text] [Related]
17. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G
J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360
[TBL] [Abstract][Full Text] [Related]
18. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ; Grisham RN; Banerjee S; Kalbacher E; Mirza MR; Romero I; Vuylsteke P; Coleman RL; Hilpert F; Oza AM; Westermann A; Oehler MK; Pignata S; Aghajanian C; Colombo N; Drill E; Cibula D; Moore KN; Christy-Bittel J; Del Campo JM; Berger R; Marth C; Sehouli J; O'Malley DM; Churruca C; Boyd AP; Kristensen G; Clamp A; Ray-Coquard I; Vergote I
J Clin Oncol; 2020 Nov; 38(32):3753-3762. PubMed ID: 32822286
[TBL] [Abstract][Full Text] [Related]
19. Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
Lazurko C; Clark M; Pulman K; Lennox G; May T; Fazelzad R; Gien LT; Zigras T
Gynecol Oncol; 2021 Oct; 163(1):209-214. PubMed ID: 34325937
[TBL] [Abstract][Full Text] [Related]
20. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
Murumägi A; Ungureanu D; Khan S; Arjama M; Välimäki K; Ianevski A; Ianevski P; Bergström R; Dini A; Kanerva A; Koivisto-Korander R; Tapper J; Lassus H; Loukovaara M; Mägi A; Hirasawa A; Aoki D; Pietiäinen V; Pellinen T; Bützow R; Aittokallio T; Kallioniemi O
Br J Cancer; 2023 Feb; 128(4):678-690. PubMed ID: 36476658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
